Tepezza hearing loss and tinnitus lawsuit MDL 3079 in the Northern District of Illinois: Horizon Therapeutics (now Amgen subsidiary) failure-to-warn allegations, FDA label hearing impairment warnings, who qualifies, document checklist, and how to find an MDL attorney in 2026.
Demanda Tepezza (teprotumumab) por pérdida auditiva y tinnitus MDL 3079 en el Distrito Norte de Illinois: Horizon Therapeutics (subsidiaria de Amgen) no advirtió sobre sordera permanente, criterios de elegibilidad, lista de documentos y cómo encontrar un abogado de MDL bilingüe en 2026.
Tepezza(테프로투무맙) 청력 손실 소송 MDL 3079 — 일리노이 북부 연방법원 Tharp 판사, Horizon Therapeutics·Amgen 피고, FDA 라벨 경고 미흡 의혹, 영구 난청·이명 피해자 청구 자격과 한국 거주자 참여 경로 실무 정리.
Análisis de Amgen 2026: MariTide GLP-1 Fase 3, integración de Horizon Therapeutics, erosión por biosimilares de Prolia y Enbrel, negociación de precios CMS-IRA y fiscalidad para inversores españoles.
Amgen 2026 analysis: MariTide GLP-1 Phase 3 inflection, Horizon Therapeutics integration, biosimilar erosion of Prolia and Enbrel, CMS drug price negotiation risk, and how US investors should position.